Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
Type:
Grant
Filed:
December 17, 1999
Date of Patent:
March 4, 2003
Assignee:
Immunex Corporation
Inventors:
Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky, William C. Dougall
Abstract: Polypeptides capable of binding human IL-13 and/or of binding human IL-4 in the presence of IL-4 R.alpha. can be used in medicine, in diagnosis and in screening for agonists/antagonists of IL-13/IL-4. One such polypeptide is shown in FIG. 1.
Abstract: The invention concerns novel members of the endocytic type C lectin family and methods and means for producing them. The native polypeptides of the invention are characterized by containing a signal sequence, a cysteine rich domain, a fibronectin type II domain, 8 type C lectin domains, a transmembrane domain and a cytoplasmic domain. Nucleotide sequences encoding such polypeptides, vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel type C lectins are also within the scope of the invention.
Abstract: An isolated DNA molecule encodes a photoreceptive retinaldehyde-binding protein of the visual system and brain. The isolated protein is a putative receptor for an all-trans-retinylidene chromophore that absorbs light in the visible range. Antibodies are disclosed which specifically bind to such retinaldehyde binding protein. An altered retinaldehyde binding protein with a 38 amino acid deletion is an indicator of abnormality in the retinal pigment epithelium. Antibodies are also disclosed which are specific to the altered retinaldehyde binding protein.